Cercar
01/09/2021
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II
Martinez-Trufero, J, Jurado, JC, Hernandez-Leon, CN, Correa, R, Asencio, JM, Bernabeu, D, Alvarez, R, Hindi, N, Mata, C, Marquina, G, Martinez, V, Redondo, A, Floria, LJ, Gomez-Mateo, MC, Lavernia, J, Sebio, A, del Muro, XG, Martin-Broto, J, Valverde-Morales, C. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102260. PMID:34340159. IF:13.608(Q1/1D).
01/05/2025
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Puente, J, Pinto, A, Mendez-Vidal, MJ, del Muro, XG, Maroto, P, Vazquez, S, Luque-Caro, R, Anido, U, Strunz-McKendry, T, Upadhyay, A, Montes, J, Nuñez, AO, Portela, JG, Castellano, D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2025; 27(5)DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2.500(Q3/6D).
01/01/2025
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial
Palmerini, E, Pousa, AL, Grignani, G, Redondo, A, Hindi, N, Provenzano, S, Sebio, A, Martin, JAL, Valverde, C, Trufero, JM, Gutierrez, A, de Alava, E, Gomez, MPA, D'Ambrosio, L, Collini, P, Bazzocchi, A, Moura, DS, Ibrahim, T, Stacchiotti, S, Broto, JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2025; 131(1)DOI:10.1002/cncr.35628. PMID:39540661. IF:5.100(Q1/3D).
01/12/2024
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol
Salazar, J, Arranz, MJ, Martin-Broto, J, Bautista, F, Martínez-García, J, Martínez-Trufero, J, Vidal-Insua, Y, Echebarria-Barona, A, Díaz-Beveridge, R, Valverde, C, Luna, P, Vaz-Salgado, MA, Blay, P, Alvarez, R, Sebio, A. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024; 16(12)DOI:10.3390/pharmaceutics16121585. PMID:39771563. IF:5.500(Q1/1D).
01/11/2024
Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
Caballero-Borrego, M, Piedra, A, Gallego, O, López-Pousa, A, Castillo, P, Navarrete, P, Prat, A, Grau, JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology. 2024; 90(6)DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1.800(Q2/4D).
01/11/2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).